Cofrogliptin

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Cofrogliptin (HSK7653) (compound 2)，一种四氢吡喃衍生物，是一种有效的口服 DPP-4 抑制剂，具有长效降糖作用。Cofrogliptin (compound 2) 在2型糖尿病 (T2DM) 应用中具有很大的潜力。

Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) .

Cofrogliptin (HSK7653) (compound 2) has the DPP-4 inhibitory activity with an IC50 value of 4.18 nM.

Cofrogliptin (HSK7653) (compound 2) (IV: 0.5 mg/kg; PO: 2 mg/kg) exhibits extremely long half-lives and low rate of reduction of drug concentration after orally administration.Cofrogliptin (compound 2) (Single, orally, 3 mg/kg, 10 mg/kg, 30 mg/kg) increases of half-lives, has high oral exposure, low i.v. clearance and hepatic microsomal clearance after intravenous dosing. Cofrogliptin (compound 2) (Single, orally, 10 mg/kg) exhibits longe inhibition time of DPP-4 and decreases HbA1c level at the doses of 3 and 10 mg/kg in ob/ob mice. Cofrogliptin (compound 2) (Single, orally, 10 mg/kg) also has a great potential of biweekly regimen for T2DM as indicated in rhesus monkeys.Animal Model:ob/ob mice Dosage:3 mg/kg, 10 mg/kg, 30 mg/kg Administration: Single, orally, 3 mg/kg, 10 mg/kg, 30 mg/kg Result:Exhibited strong inhibition capability of plasma DPP-4 in a dose dependent manner. Animal Model:rhesus monkeys Dosage:10 mg/kg Administration:Single, orally, 10 mg/kg Result: Possessed the capability of plasma DPP-4 inhibition over 80% for at least 12 days.Remained the plasma DPP-4 inhibition rates of 76.16% and 43.41%, respectively at the end of second week and third week after administration.

——

Metabolic Enzyme/Protease

DPP

DPP-4

——

——

1844874-26-5

466.43

C18H19F5N4O3S

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 100 mg/mL (214.39 mM; 超声助溶 )

C(F)(F)(F)[C@@H]1[C@@H](C[C@H](N)[C@H](O1)C2=C(F)C=CC(F)=C2)N3CC=4C(C3)=NN(S(C)(=O)=O)C4

——

(-20℃)

With Ice Pack

≥ 2 years